Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial.

McKay R, Mills H, Werner L, Choudhury A, Choueiri T, Jacobus S, Pace A, Polacek L, Pomerantz M, Prisby J, Sweeney C, Walsh M, Taplin ME.

J Med Internet Res. 2019 May 2;21(5):e12044. doi: 10.2196/12044.

2.

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.

McKay RR, Werner L, Jacobus SJ, Jones A, Mostaghel EA, Marck BT, Choudhury AD, Pomerantz MM, Sweeney CJ, Slovin SF, Morris MJ, Kantoff PW, Taplin ME.

Cancer. 2019 Feb 15;125(4):524-532. doi: 10.1002/cncr.31836. Epub 2018 Nov 14.

PMID:
30427533
3.

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE.

Br J Cancer. 2018 Sep;119(6):707-712. doi: 10.1038/s41416-018-0261-0. Epub 2018 Sep 17.

PMID:
30220708
4.

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV.

Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.

5.

Decision on performing interim analysis for comparative clinical trials.

Pak K, Jacobus S, Uno H.

Contemp Clin Trials Commun. 2017 Aug 16;7:224-230. doi: 10.1016/j.conctc.2017.08.001. eCollection 2017 Sep.

6.

Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma.

Bullock A, Stuart K, Jacobus S, Abrams T, Wadlow R, Goldstein M, Miksad R.

J Gastrointest Oncol. 2017 Dec;8(6):945-952. doi: 10.21037/jgo.2017.06.06.

7.

Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy.

Tripathi A, Jacobus S, Feldman H, Choueiri TK, Harshman LC.

Clin Genitourin Cancer. 2017 Jun;15(3):396-402. doi: 10.1016/j.clgc.2016.12.009. Epub 2016 Dec 13.

PMID:
28040423
8.

Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy.

McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME.

Clin Genitourin Cancer. 2017 Apr;15(2):e289-e298. doi: 10.1016/j.clgc.2016.08.015. Epub 2016 Aug 20.

PMID:
27651103
9.

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.

Biran N, Jacobus S, Vesole DH, Callander NS, Fonseca R, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR, Siegel DS.

Blood Cancer J. 2016 Sep 2;6(9):e466. doi: 10.1038/bcj.2016.68.

10.

Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.

Jacobus SJ, Rajkumar SV, Weiss M, Stewart AK, Stadtmauer EA, Callander NS, Dreosti LM, Lacy MQ, Fonseca R.

Blood Cancer J. 2016 Jul 29;6(7):e448. doi: 10.1038/bcj.2016.55. No abstract available.

11.

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.

Mahoney KM, Jacobus S, Bhatt RS, Song J, Carvo I, Cheng SC, Simpson M, Fay AP, Puzanov I, Michaelson MD, Atkins MB, McDermott DF, Signoretti S, Choueiri TK.

Clin Genitourin Cancer. 2016 Aug;14(4):304-313.e6. doi: 10.1016/j.clgc.2016.02.007. Epub 2016 Feb 23.

PMID:
27036973
12.

Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.

Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV.

Blood. 2015 Sep 10;126(11):1294-301. doi: 10.1182/blood-2014-12-613927. Epub 2015 Jul 8.

13.

Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, Schrag D, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, Wei LJ.

J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30.

14.

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE.

J Clin Oncol. 2014 Jun 20;32(18):1889-94. doi: 10.1200/JCO.2013.52.4785. Epub 2014 May 12.

PMID:
24821883
15.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE.

Cancer Discov. 2014 May;4(5):546-53. doi: 10.1158/2159-8290.CD-13-0353. Epub 2014 Mar 13.

16.

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.

Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, Jelinek DF, Carpten J, Fonseca R.

Blood. 2013 Apr 18;121(16):3147-52. doi: 10.1182/blood-2012-07-443606. Epub 2013 Feb 19.

17.

Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.

Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus S, Morrow GR; University of Rochester Cancer Center and the Eastern Cooperative Oncology Group.

Leukemia. 2012 Dec;26(12):2517-20. doi: 10.1038/leu.2012.124. Epub 2012 May 8.

18.

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW.

J Clin Oncol. 2012 Feb 10;30(5):507-12. doi: 10.1200/JCO.2011.37.7002. Epub 2011 Dec 19.

19.

Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.

Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R.

Br J Haematol. 2011 Nov;155(3):340-8. doi: 10.1111/j.1365-2141.2011.08849.x. Epub 2011 Sep 9.

20.

The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.

Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, Lee GS, Kantoff PW.

Cancer Prev Res (Phila). 2011 Dec;4(12):2044-50. doi: 10.1158/1940-6207.CAPR-11-0283. Epub 2011 Sep 7.

21.

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV.

Blood. 2011 Oct 20;118(16):4359-62. doi: 10.1182/blood-2011-03-342089. Epub 2011 Aug 22.

22.

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.

Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A.

Cancer. 2011 Feb 1;117(3):517-25. doi: 10.1002/cncr.25394. Epub 2010 Sep 22.

23.

Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.

Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR.

Leukemia. 2010 Aug;24(8):1406-11. doi: 10.1038/leu.2010.129. Epub 2010 Jun 10.

24.

Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.

Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE.

BJU Int. 2010 May;105(10):1392-6. doi: 10.1111/j.1464-410X.2009.08971.x. Epub 2009 Oct 23.

25.

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR; Eastern Cooperative Oncology Group.

Lancet Oncol. 2010 Jan;11(1):29-37. doi: 10.1016/S1470-2045(09)70284-0. Epub 2009 Oct 21. Erratum in: Lancet Oncol. 2010 Jan;11(1):14.

27.

Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.

Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, Greipp PR.

Leuk Res. 2009 Nov;33(11):1485-9. doi: 10.1016/j.leukres.2009.01.020. Epub 2009 Feb 24.

28.

Absence of relationship between steroid hormone levels and prostate cancer tumor grade.

Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK.

Urology. 2009 Feb;73(2):356-61; discussion 361-2. doi: 10.1016/j.urology.2008.07.068. Epub 2008 Nov 26.

PMID:
19036418
29.

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival.

Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D, Morgan G.

BMC Med. 2008 Sep 8;6:26. doi: 10.1186/1741-7015-6-26.

30.

Relationship between serum adiponectin and prostate cancer grade.

Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C.

Prostate. 2008 Oct 1;68(14):1592-8. doi: 10.1002/pros.20823.

PMID:
18646046
31.

Clinical and biological significance of RAS mutations in multiple myeloma.

Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, Kyle RA, Henderson KJ, Van Wier S, Greipp P, Van Ness B, Fonseca R.

Leukemia. 2008 Dec;22(12):2280-4. doi: 10.1038/leu.2008.142. Epub 2008 Jun 5. No abstract available.

32.

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.

Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.

BJU Int. 2008 Feb;101(3):308-12. doi: 10.1111/j.1464-410X.2007.07331.x.

33.

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.

Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK; Prostate Cancer Clinical Trials Consortium.

Cancer. 2008 Feb 1;112(3):521-6.

34.
35.

Clinical significance of TP53 mutation in myeloma.

Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Rajkumar SV, Fonseca R.

Leukemia. 2007 Mar;21(3):582-4. Epub 2007 Jan 11. No abstract available.

PMID:
17215851
36.

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.

Chng WJ, Santana-Dávila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, Oken MM, Henderson K, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R.

Leukemia. 2006 May;20(5):807-13.

PMID:
16511510
38.

Reactivity to smoking cues and relapse: two studies of discriminant validity.

Abrams DB, Monti PM, Carey KB, Pinto RP, Jacobus SI.

Behav Res Ther. 1988;26(3):225-33. No abstract available.

PMID:
3408457
39.

Nicotine dependence and likelihood of quitting smoking.

Pinto RP, Abrams DB, Monti PM, Jacobus SI.

Addict Behav. 1987;12(4):371-4.

PMID:
3687521
40.

Psychosocial stress and coping in smokers who relapse or quit.

Abrams DB, Monti PM, Pinto RP, Elder JP, Brown RA, Jacobus SI.

Health Psychol. 1987;6(4):289-303.

PMID:
3301320
41.
42.

Proceedings: Reaction of phenylmethanesulfonyl subtilisin with hydrogen peroxide.

Jacobus S.

Isr J Med Sci. 1975 Nov;11(11):1168-9. No abstract available.

PMID:
1205728

Supplemental Content

Loading ...
Support Center